Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Clinical trial NCT06846281 · RECRUITING
Trial details
- NCT number
- NCT06846281
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-23
- Primary completion
- 2029-07-24
- Enrollment
- 360
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.